Literature DB >> 11002314

Metabolism of alternative substrates and the bioenergetic status of EMT6 tumor cell spheroids.

J P Wehrle1, C E Ng, K A McGovern, N R Aiken, D C Shungu, E M Chance, J D Glickson.   

Abstract

In order to evaluate the ability of EMT6/Ro multicellular spheroids to utilize various pathways of energy production, (13)C and (31)P MRS have been employed to monitor the metabolism of glucose, glutamine, acetate and propionate. EMT6/Ro spheroids perfused with culture medium containing 5.5 mM glucose maintain stable levels of nucleotide triphosphates (NTP) and phosphocreatine (PCr) for up to 48 h, even in the absence of glutamine. The metabolism of 1-(13)C-glucose was almost entirely to 3-(13)C-lactate (88 +/- 12%, n = 7), even though the perfusion medium was equilibrated with 95% O(2). Labeling was also observed in other glycolytic metabolites, primarily alanine and alpha-glycerolphosphate. A low level of (13)C labeling in glutamate, indicative of mitochondrial oxidative metabolism (TCA cycle), was consistently detected when spheroids were perfused with 1-(13)C-glucose, almost exclusively in the C4 position of glutamate. Labeling of glutamate C2 and C3 was always less than 20% of the labeling in C4 and was usually undetectable. No evidence of adjacent carbon labeling in individual glutamate molecules (indicative of multiple cycles of label incorporation) was found, even in high-resolution (13)C NMR spectra of extracts from cells or spheroids. Despite the predominantly glycolytic metabolism of glucose, the mitochondrial substrate glutamine (2 mM, in the presence of < or =0.5 mM glucose from fetal bovine serum), supported stable levels of NTP and PCr in the tumor cells for up to 12 h. In the presence of 2.5 mM acetate, the bioenergetic status of cells in EMT6 spheroids declined slowly but measurably, and no incorporation of label from 2-(13)C-acetate into other metabolites was detected either in intact perfused spheroids or in high-resolution spectra of extracts. In contrast, when the anaplerotic TCA cycle substrate 3-(13)C-propionate replaced acetate, the high-energy phosphate levels in EMT6/Ro spheroids were somewhat reduced, but stabilized at a new lower level. Incubation of spheroids with 3-(13)C-propionate (with natural abundance glucose and glutamine) resulted in label detectable in the C2 and C3 of glutamate, but the primary labeled compound was methylmalonate, an intermediate in propionate metabolism. Addition of vitamin B(12), a cofactor for methylmalonyl CoA reductase, to the growth medium 24 h prior to perfusion with propionate resulted in the elimination of the methylmalonate resonance. A variety of 2- and 3-labeled metabolites were detected, including succinate, malate and glutamate. Labeling of C2 and C3 of lactate implicated cytoplasmic malic enzyme activity. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11002314     DOI: 10.1002/1099-1492(200010)13:6<349::aid-nbm652>3.0.co;2-x

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  14 in total

Review 1.  A review of spatial computational models for multi-cellular systems, with regard to intestinal crypts and colorectal cancer development.

Authors:  Giovanni De Matteis; Alex Graudenzi; Marco Antoniotti
Journal:  J Math Biol       Date:  2012-05-08       Impact factor: 2.259

2.  Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Metabolomics       Date:  2016-06-29       Impact factor: 4.290

3.  Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate.

Authors:  Yakir S Levin; Mark J Albers; Thomas N Butler; Daniel Spielman; Donna M Peehl; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2009-11       Impact factor: 4.668

4.  Spatio-Temporal Dynamics of Hypoxia during Radiotherapy.

Authors:  Harald Kempf; Marcus Bleicher; Michael Meyer-Hermann
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

5.  Comparison of three ¹⁸F-labeled carboxylic acids with ¹⁸F-FDG of the differentiation tumor from inflammation in model mice.

Authors:  Hongliang Wang; Ganghua Tang; Kongzhen Hu; Tingting Huang; Xiang Liang; Zhifang Wu; Sijin Li
Journal:  BMC Med Imaging       Date:  2016-01-12       Impact factor: 1.930

6.  Rhabdomyosarcoma cells show an energy producing anabolic metabolic phenotype compared with primary myocytes.

Authors:  Teresa W M Fan; Magda Kucia; Kacper Jankowski; Richard M Higashi; Janina Ratajczak; Marius Z Ratajczak; Andrew N Lane
Journal:  Mol Cancer       Date:  2008-10-21       Impact factor: 27.401

7.  In silico analysis of cell cycle synchronisation effects in radiotherapy of tumour spheroids.

Authors:  Harald Kempf; Haralampos Hatzikirou; Marcus Bleicher; Michael Meyer-Hermann
Journal:  PLoS Comput Biol       Date:  2013-11-14       Impact factor: 4.475

8.  Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment.

Authors:  Rui V Simões; Inna S Serganova; Natalia Kruchevsky; Avigdor Leftin; Alexander A Shestov; Howard T Thaler; George Sukenick; Jason W Locasale; Ronald G Blasberg; Jason A Koutcher; Ellen Ackerstaff
Journal:  Neoplasia       Date:  2015-08       Impact factor: 5.715

9.  Expression of cytosolic malic enzyme (ME1) is associated with disease progression in human oral squamous cell carcinoma.

Authors:  Chie Nakashima; Kazuhiko Yamamoto; Rina Fujiwara-Tani; Yi Luo; Sayako Matsushima; Kiyomu Fujii; Hitoshi Ohmori; Tomonori Sasahira; Takamitsu Sasaki; Yasuhiko Kitadai; Tadaaki Kirita; Hiroki Kuniyasu
Journal:  Cancer Sci       Date:  2018-05-01       Impact factor: 6.716

Review 10.  Resolving Metabolic Heterogeneity in Experimental Models of the Tumor Microenvironment from a Stable Isotope Resolved Metabolomics Perspective.

Authors:  Teresa W-M Fan; Richard M Higashi; Yelena Chernayavskaya; Andrew N Lane
Journal:  Metabolites       Date:  2020-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.